NCT06332872

Brief Summary

The goal of this clinical trial is to Comparison effectiveness of Oral ivermectin , 1% Permethrin shampoo and 4% Dimeticone liquid gel in the treatment of Pediculosis capitis, to assess the prevalence of lice and associated risk factors between severity groups by using questionnaire-based surveys and diagnostic tests among school children in Baan Nayao, Chachoengsao Province, Thailand. The main questions it aims to answer are

  • What is more effective between Oral ivermectin , 1% Permethrin shampoo and 4%Dimeticone liquid gel in the treatment of Pediculosis capitis in school children in Baan Nayao, Chachoengsao Province, Thailand?
  • What is Prevalence and risk factors of being infected with in head lice in school and community?
  • What is Side effects of Oral ivermectin , 1% Permethrin shampoo and 4%Dimeticone liquid gel? Participants will receive three different drugs are
  • oral ivermectin
  • 4% Dimeticone liquid gel
  • 1% Permethrin shampoo Participants voluntarily received oral ivermectin as per medical prescription, with treatment outcomes, side effects, and satisfaction levels monitored following two treatment cycles. Those exhibiting persistent lice infestations were subsequently treated with 1% permethrin shampoo, the standard treatment, while alternatives were provided for individuals allergic to permethrin. These findings will contribute to formulating tailored, effective, and safe treatment regimens for future patients.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
117

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Dec 2023

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 15, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 18, 2024

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

March 20, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 27, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2024

Completed
Last Updated

March 27, 2024

Status Verified

March 1, 2024

Enrollment Period

3 months

First QC Date

March 20, 2024

Last Update Submit

March 20, 2024

Conditions

Keywords

Pediculosis capitishead licepediculicidesSchoolChildrenPermethrinShampooIvermectinDimenticonegelliquid gelpediculosis

Outcome Measures

Primary Outcomes (1)

  • Comparison effectiveness of Oral ivermectin , 1% Permethrin shampoo and 4% Dimeticone liquid gel in the treatment of Pediculosis capitis

    Treatment of Pediculosis capitis was considered effective by the absence of live lice

    From enrollment to the end of treatment at 28 days

Secondary Outcomes (3)

  • Prevalence of head louse infestation among school children in Chachoengsao Province, Thailand

    From enrollment to the end of screening at 28 days

  • Side effects of Oral ivermectin , 1% Permethrin shampoo and 4%Dimeticone liquid gel

    From enrollment to the end of treatment at 28 days

  • The association factor of head lice infestation among school children in Chachoengsao Province, Thailand

    From the enrollment to the end of treatment at 28 days

Study Arms (3)

Oral ivermectin

EXPERIMENTAL

For the treatment of head lice infestation, participants are receiving two single doses of oral ivermectin on days 0 and 7 of the experiment. (spaced 7 days apart)

Drug: Oral Ivermectin

Dimeticone liquid gel

EXPERIMENTAL

For the treatment of head lice infestation, participants are receiving one application of 4% dimenticone liquid gel on day 0 of the experiment.

Drug: 4% dimenticone liquid gel

Permethrin shampoo

NO INTERVENTION

Participants are receiving two applications of 1% permethrin shampoo, which is the current drug of choice for Pediculosis capitis, on days 0 and 7. This group is defined as a control group.

Interventions

Oral formulation (3mg tablet) Dosage: 2 single doses of 200 mcg/kg given 7 days apart

Oral ivermectin

topical formulation (liquid gel) only 1 application

Dimeticone liquid gel

Eligibility Criteria

Age6 Years - 13 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • The participants are studying in Na Yao border patrol police school, Ban Na Isan border patrol police school or Phu Ngam wittaya school.
  • Approved consent from the participants' caretaker

You may not qualify if:

  • History of Allergic sensitization to these substances
  • The participants with chronic scalp disorder
  • Those who had used a pediculicide within the previous two weeks
  • Those who had recently used bleaches, dyes, or permanent wave products
  • Anyone taking trimethoprim or cotrimoxazole at evaluation or during the previous four weeks
  • Those who had participated in another clinical trial within one month
  • Pregnancy
  • Body weight \< 20 kg.
  • Loss to follow up in a second dose

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Phramongkutklao college of medicine

Bangkok, Thailand

Location

MeSH Terms

Conditions

Lice Infestations

Interventions

Ivermectin

Condition Hierarchy (Ancestors)

Ectoparasitic InfestationsSkin Diseases, ParasiticParasitic DiseasesInfectionsSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

MacrolidesPolyketidesLactonesOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 20, 2024

First Posted

March 27, 2024

Study Start

December 15, 2023

Primary Completion

March 18, 2024

Study Completion

May 1, 2024

Last Updated

March 27, 2024

Record last verified: 2024-03

Locations